Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Buy
85
VBIZF Quote, Financials, Valuation and Earnings
Last price:
$0.3434
Seasonality move
:
7.37%
Day range:
$0.3434 - $0.3434
52-week range:
$0.1294 - $0.4294
Dividend yield:
0%
P/E ratio:
19.39x
P/S ratio:
3.15x
P/B ratio:
0.76x
Volume:
--
Avg. volume:
3.4K
1-year change:
165.38%
Market cap:
$724.5M
Revenue:
$276M
EPS (TTM):
$0.01
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
VBIZF
Viva Biotech Holdings
|
-- | -- | -- | -- | -- |
|
ASCLF
Ascletis Pharma, Inc.
|
-- | -- | -- | -- | -- |
|
CASI
CASI Pharmaceuticals, Inc.
|
-- | -- | -100% | -- | $4.00 |
|
SVA
Sinovac Biotech Ltd.
|
-- | -- | -- | -- | -- |
|
WXXWY
WuXi Biologics (Cayman), Inc.
|
-- | -- | -- | -- | -- |
|
ZLAB
Zai Lab Ltd.
|
$122.7M | -$0.42 | 17.43% | -30.7% | $43.42 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
VBIZF
Viva Biotech Holdings
|
$0.3434 | -- | $724.5M | 19.39x | $0.00 | 0% | 3.15x |
|
ASCLF
Ascletis Pharma, Inc.
|
$2.2550 | -- | $2.2B | -- | $0.00 | 0% | 6,719.85x |
|
CASI
CASI Pharmaceuticals, Inc.
|
$0.77 | $4.00 | $15.7M | -- | $0.00 | 0% | 0.45x |
|
SVA
Sinovac Biotech Ltd.
|
$6.47 | -- | $464.9M | -- | $55.00 | 0% | 1.50x |
|
WXXWY
WuXi Biologics (Cayman), Inc.
|
$10.42 | -- | $21.2B | 29.93x | $0.00 | 0% | 7.86x |
|
ZLAB
Zai Lab Ltd.
|
$20.04 | $43.42 | $2.2B | -- | $0.00 | 0% | 4.87x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
VBIZF
Viva Biotech Holdings
|
24.82% | -7.949 | -- | 1.26x |
|
ASCLF
Ascletis Pharma, Inc.
|
-- | -8.397 | -- | 12.82x |
|
CASI
CASI Pharmaceuticals, Inc.
|
-274.41% | -0.389 | 55.28% | 0.19x |
|
SVA
Sinovac Biotech Ltd.
|
3.46% | 7.263 | 12.91% | 11.22x |
|
WXXWY
WuXi Biologics (Cayman), Inc.
|
5.93% | -0.126 | -- | 1.98x |
|
ZLAB
Zai Lab Ltd.
|
22.4% | -0.192 | 5.85% | 2.56x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
VBIZF
Viva Biotech Holdings
|
-- | -- | -1.17% | -1.8% | -- | -- |
|
ASCLF
Ascletis Pharma, Inc.
|
-- | -- | -13.95% | -13.95% | -- | -- |
|
CASI
CASI Pharmaceuticals, Inc.
|
$706K | -$10.2M | -405.32% | -70405.41% | -333.14% | -- |
|
SVA
Sinovac Biotech Ltd.
|
-- | -- | -1.02% | -1.05% | -- | -- |
|
WXXWY
WuXi Biologics (Cayman), Inc.
|
-- | -- | 7.16% | 7.53% | -- | -- |
|
ZLAB
Zai Lab Ltd.
|
$69.3M | -$48.9M | -21.74% | -26.7% | -42.05% | -$44.5M |
Viva Biotech Holdings vs. Competitors
-
Which has Higher Returns VBIZF or ASCLF?
Ascletis Pharma, Inc. has a net margin of -- compared to Viva Biotech Holdings's net margin of --. Viva Biotech Holdings's return on equity of -1.8% beat Ascletis Pharma, Inc.'s return on equity of -13.95%.
Company Gross Margin Earnings Per Share Invested Capital VBIZFViva Biotech Holdings-- -- $694.7M ASCLFAscletis Pharma, Inc.-- -- $269.3M -
What do Analysts Say About VBIZF or ASCLF?
Viva Biotech Holdings has a consensus price target of --, signalling downside risk potential of --. On the other hand Ascletis Pharma, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Viva Biotech Holdings has higher upside potential than Ascletis Pharma, Inc., analysts believe Viva Biotech Holdings is more attractive than Ascletis Pharma, Inc..
Company Buy Ratings Hold Ratings Sell Ratings VBIZFViva Biotech Holdings0 0 0 ASCLFAscletis Pharma, Inc.0 0 0 -
Is VBIZF or ASCLF More Risky?
Viva Biotech Holdings has a beta of 0.502, which suggesting that the stock is 49.774% less volatile than S&P 500. In comparison Ascletis Pharma, Inc. has a beta of -19.220, suggesting its less volatile than the S&P 500 by 2022.009%.
-
Which is a Better Dividend Stock VBIZF or ASCLF?
Viva Biotech Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ascletis Pharma, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Viva Biotech Holdings pays -- of its earnings as a dividend. Ascletis Pharma, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios VBIZF or ASCLF?
Viva Biotech Holdings quarterly revenues are --, which are smaller than Ascletis Pharma, Inc. quarterly revenues of --. Viva Biotech Holdings's net income of -- is lower than Ascletis Pharma, Inc.'s net income of --. Notably, Viva Biotech Holdings's price-to-earnings ratio is 19.39x while Ascletis Pharma, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Viva Biotech Holdings is 3.15x versus 6,719.85x for Ascletis Pharma, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income VBIZFViva Biotech Holdings3.15x 19.39x -- -- ASCLFAscletis Pharma, Inc.6,719.85x -- -- --
-
Which has Higher Returns VBIZF or CASI?
CASI Pharmaceuticals, Inc. has a net margin of -- compared to Viva Biotech Holdings's net margin of -353.92%. Viva Biotech Holdings's return on equity of -1.8% beat CASI Pharmaceuticals, Inc.'s return on equity of -70405.41%.
Company Gross Margin Earnings Per Share Invested Capital VBIZFViva Biotech Holdings-- -- $694.7M CASICASI Pharmaceuticals, Inc.22.96% -$0.68 -$6.9M -
What do Analysts Say About VBIZF or CASI?
Viva Biotech Holdings has a consensus price target of --, signalling downside risk potential of --. On the other hand CASI Pharmaceuticals, Inc. has an analysts' consensus of $4.00 which suggests that it could grow by 422.81%. Given that CASI Pharmaceuticals, Inc. has higher upside potential than Viva Biotech Holdings, analysts believe CASI Pharmaceuticals, Inc. is more attractive than Viva Biotech Holdings.
Company Buy Ratings Hold Ratings Sell Ratings VBIZFViva Biotech Holdings0 0 0 CASICASI Pharmaceuticals, Inc.1 0 0 -
Is VBIZF or CASI More Risky?
Viva Biotech Holdings has a beta of 0.502, which suggesting that the stock is 49.774% less volatile than S&P 500. In comparison CASI Pharmaceuticals, Inc. has a beta of 0.866, suggesting its less volatile than the S&P 500 by 13.412%.
-
Which is a Better Dividend Stock VBIZF or CASI?
Viva Biotech Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CASI Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Viva Biotech Holdings pays -- of its earnings as a dividend. CASI Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios VBIZF or CASI?
Viva Biotech Holdings quarterly revenues are --, which are smaller than CASI Pharmaceuticals, Inc. quarterly revenues of $3.1M. Viva Biotech Holdings's net income of -- is lower than CASI Pharmaceuticals, Inc.'s net income of -$10.9M. Notably, Viva Biotech Holdings's price-to-earnings ratio is 19.39x while CASI Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Viva Biotech Holdings is 3.15x versus 0.45x for CASI Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income VBIZFViva Biotech Holdings3.15x 19.39x -- -- CASICASI Pharmaceuticals, Inc.0.45x -- $3.1M -$10.9M
-
Which has Higher Returns VBIZF or SVA?
Sinovac Biotech Ltd. has a net margin of -- compared to Viva Biotech Holdings's net margin of --. Viva Biotech Holdings's return on equity of -1.8% beat Sinovac Biotech Ltd.'s return on equity of -1.05%.
Company Gross Margin Earnings Per Share Invested Capital VBIZFViva Biotech Holdings-- -- $694.7M SVASinovac Biotech Ltd.-- -- $11.8B -
What do Analysts Say About VBIZF or SVA?
Viva Biotech Holdings has a consensus price target of --, signalling downside risk potential of --. On the other hand Sinovac Biotech Ltd. has an analysts' consensus of -- which suggests that it could fall by --. Given that Viva Biotech Holdings has higher upside potential than Sinovac Biotech Ltd., analysts believe Viva Biotech Holdings is more attractive than Sinovac Biotech Ltd..
Company Buy Ratings Hold Ratings Sell Ratings VBIZFViva Biotech Holdings0 0 0 SVASinovac Biotech Ltd.0 0 0 -
Is VBIZF or SVA More Risky?
Viva Biotech Holdings has a beta of 0.502, which suggesting that the stock is 49.774% less volatile than S&P 500. In comparison Sinovac Biotech Ltd. has a beta of 0.746, suggesting its less volatile than the S&P 500 by 25.394%.
-
Which is a Better Dividend Stock VBIZF or SVA?
Viva Biotech Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sinovac Biotech Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $55.00 per share. Viva Biotech Holdings pays -- of its earnings as a dividend. Sinovac Biotech Ltd. pays out -328.35% of its earnings as a dividend.
-
Which has Better Financial Ratios VBIZF or SVA?
Viva Biotech Holdings quarterly revenues are --, which are smaller than Sinovac Biotech Ltd. quarterly revenues of --. Viva Biotech Holdings's net income of -- is lower than Sinovac Biotech Ltd.'s net income of --. Notably, Viva Biotech Holdings's price-to-earnings ratio is 19.39x while Sinovac Biotech Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Viva Biotech Holdings is 3.15x versus 1.50x for Sinovac Biotech Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income VBIZFViva Biotech Holdings3.15x 19.39x -- -- SVASinovac Biotech Ltd.1.50x -- -- --
-
Which has Higher Returns VBIZF or WXXWY?
WuXi Biologics (Cayman), Inc. has a net margin of -- compared to Viva Biotech Holdings's net margin of --. Viva Biotech Holdings's return on equity of -1.8% beat WuXi Biologics (Cayman), Inc.'s return on equity of 7.53%.
Company Gross Margin Earnings Per Share Invested Capital VBIZFViva Biotech Holdings-- -- $694.7M WXXWYWuXi Biologics (Cayman), Inc.-- -- $6.6B -
What do Analysts Say About VBIZF or WXXWY?
Viva Biotech Holdings has a consensus price target of --, signalling downside risk potential of --. On the other hand WuXi Biologics (Cayman), Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Viva Biotech Holdings has higher upside potential than WuXi Biologics (Cayman), Inc., analysts believe Viva Biotech Holdings is more attractive than WuXi Biologics (Cayman), Inc..
Company Buy Ratings Hold Ratings Sell Ratings VBIZFViva Biotech Holdings0 0 0 WXXWYWuXi Biologics (Cayman), Inc.0 0 0 -
Is VBIZF or WXXWY More Risky?
Viva Biotech Holdings has a beta of 0.502, which suggesting that the stock is 49.774% less volatile than S&P 500. In comparison WuXi Biologics (Cayman), Inc. has a beta of -0.062, suggesting its less volatile than the S&P 500 by 106.225%.
-
Which is a Better Dividend Stock VBIZF or WXXWY?
Viva Biotech Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. WuXi Biologics (Cayman), Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Viva Biotech Holdings pays -- of its earnings as a dividend. WuXi Biologics (Cayman), Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios VBIZF or WXXWY?
Viva Biotech Holdings quarterly revenues are --, which are smaller than WuXi Biologics (Cayman), Inc. quarterly revenues of --. Viva Biotech Holdings's net income of -- is lower than WuXi Biologics (Cayman), Inc.'s net income of --. Notably, Viva Biotech Holdings's price-to-earnings ratio is 19.39x while WuXi Biologics (Cayman), Inc.'s PE ratio is 29.93x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Viva Biotech Holdings is 3.15x versus 7.86x for WuXi Biologics (Cayman), Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income VBIZFViva Biotech Holdings3.15x 19.39x -- -- WXXWYWuXi Biologics (Cayman), Inc.7.86x 29.93x -- --
-
Which has Higher Returns VBIZF or ZLAB?
Zai Lab Ltd. has a net margin of -- compared to Viva Biotech Holdings's net margin of -30.98%. Viva Biotech Holdings's return on equity of -1.8% beat Zai Lab Ltd.'s return on equity of -26.7%.
Company Gross Margin Earnings Per Share Invested Capital VBIZFViva Biotech Holdings-- -- $694.7M ZLABZai Lab Ltd.59.62% -$0.33 $979.3M -
What do Analysts Say About VBIZF or ZLAB?
Viva Biotech Holdings has a consensus price target of --, signalling downside risk potential of --. On the other hand Zai Lab Ltd. has an analysts' consensus of $43.42 which suggests that it could grow by 116.67%. Given that Zai Lab Ltd. has higher upside potential than Viva Biotech Holdings, analysts believe Zai Lab Ltd. is more attractive than Viva Biotech Holdings.
Company Buy Ratings Hold Ratings Sell Ratings VBIZFViva Biotech Holdings0 0 0 ZLABZai Lab Ltd.8 1 0 -
Is VBIZF or ZLAB More Risky?
Viva Biotech Holdings has a beta of 0.502, which suggesting that the stock is 49.774% less volatile than S&P 500. In comparison Zai Lab Ltd. has a beta of 0.879, suggesting its less volatile than the S&P 500 by 12.141%.
-
Which is a Better Dividend Stock VBIZF or ZLAB?
Viva Biotech Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Zai Lab Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Viva Biotech Holdings pays -- of its earnings as a dividend. Zai Lab Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios VBIZF or ZLAB?
Viva Biotech Holdings quarterly revenues are --, which are smaller than Zai Lab Ltd. quarterly revenues of $116.2M. Viva Biotech Holdings's net income of -- is lower than Zai Lab Ltd.'s net income of -$36M. Notably, Viva Biotech Holdings's price-to-earnings ratio is 19.39x while Zai Lab Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Viva Biotech Holdings is 3.15x versus 4.87x for Zai Lab Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income VBIZFViva Biotech Holdings3.15x 19.39x -- -- ZLABZai Lab Ltd.4.87x -- $116.2M -$36M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Buy
55
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Sell
50
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 35x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 29x
Alerts
Buy
77
RNG alert for Feb 21
RingCentral, Inc. [RNG] is up 34.37% over the past day.
Sell
9
FROG alert for Feb 21
JFrog Ltd. [FROG] is down 24.98% over the past day.
Buy
72
SNSE alert for Feb 21
Sensei Biotherapeutics, Inc. [SNSE] is up 23.81% over the past day.
